Biotron Ltd has released a press release.
Significant Immunological Outcomes in BIT225 HIV-1 Trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Biotron
- Update on Progress of BIT225 Phase 2 HIV-1 Clinical Trial
- Response to ASX Appendix 4C Query
- Biotron Compounds Demonstrate Activity Against HBV
- $1.6 Million R&D Tax Incentive Received
- BIT225 Phase 2 HIV-1 Clinical Trial Update
Later from Biotron
- $1.07 million R&D Tax Incentive Received
- Biotron Secures $4.7 Million Underwriting Agreement
- Response to ASX aware letter
- Presentation of BIT225-009 hiv-1 phase 2 data
- Presentation at BIO 2019
Follow Biotron into a list and get an email when it puts out news.
Follow Biotron